tbuckley/cabot-search huggingface dataset:
Nutritional Status, Dietary Intake, and Nutrition-Related Interventions Among Older Adults With Type 1 Diabetes: A Systematic Review and Call for More Evidence Toward Clinical Guidelines
Authors: Angelica Cristello Sarteau, Gabriella Ercolino, Rashmi Muthukkumar, Angela Fruik, Elizabeth J. Mayer-Davis, Anna R. Kahkoska
Journal: Diabetes Care (2024)

There is an emerging population of older adults (≥65 years) living with type 1 diabetes. Optimizing health through nutrition during this life stage is challenged by multiple and ongoing changes in diabetes management, comorbidities, and lifestyle factors. There is a need to understand nutritional status, dietary intake, and nutrition-related interventions that may maximize well-being throughout the life span in type 1 diabetes, in addition to nutrition recommendations from clinical guidelines and consensus reports. Three reviewers used Cochrane guidelines to screen original research (January 1993-2023) and guidelines (2012-2023) in two databases (MEDLINE and CENTRAL) to characterize nutrition evidence in this population. We found limited original research explicitly focused on nutrition and diet in adults ≥65 years of age with type 1 diabetes (six experimental studies, five observational studies) and meta-analyses/reviews (one scoping review), since in the majority of analyses individuals ≥65 years of age were combined with those age ≥18 years, with diverse diabetes durations, and also individuals with type 1 and type 2 diabetes were combined. Further, existing clinical guidelines (n = 10) lacked specificity and evidence to guide clinical practice and self-management behaviors in this population. From a scientific perspective, little is known about nutrition and diet among older adults with type 1 diabetes, including baseline nutrition status, dietary intake and eating behaviors, and the impact of nutrition interventions on key clinical and patient-oriented outcomes. This likely reflects the population's recent emergence and unique considerations. Addressing these gaps is foundational to developing evidence-based nutrition practices and guidelines for older adults living with type 1 diabetes.
Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma
Authors: Syed N. Rahman, Jessica B. Long, Sarah J. Westvold, Michael S. Leapman, Lisa P. Spees, Michael E. Hurwitz, Hannah D. McManus, Cary P. Gross, Stephanie B. Wheeler, Michaela A. Dinan
Journal: JAMA Network Open (2024)

Area-level measures of sociodemographic disadvantage may be associated with racial and ethnic disparities with respect to receipt of treatment for metastatic renal cell carcinoma (mRCC) but have not been investigated previously, to our knowledge.
USPSTF Breast Cancer Screening Guidelines Do Not Go Far Enough
Authors: Wendie A. Berg
Journal: JAMA Oncology (2024)

US Preventive Services Task Force; Wanda K. Nicholson, MD, MPH, MBA; Michael Silverstein, MD, MPH; John B. Wong, MD; Michael J. Barry, MD; David Chelmow, MD; Tumaini Rucker Coker, MD, MBA; Esa M. Davis, MD, MPH; Carlos Roberto Jaén, MD, PhD, MS; Marie Krousel-Wood, MD, MSPH; Sei Lee, MD, MAS; Li Li, MD, PhD, MPH; Carol M. Mangione, MD, MSPH; Goutham Rao, MD; John M. Ruiz, PhD; James J. Stevermer, MD, MSPH; Joel Tsevat, MD, MPH; Sandra Millon Underwood, PhD, RN; Sarah Wiehe, MD, MPH
Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers
Authors: Ji Son, Yingao Zhang, Heather Lin, Oriol Mirallas, Pablo Alvarez Ballesteros, Mirella Nardo, Natalie Clark, R. Tyler Hillman, Erick Campbell, Vijaykumar Holla, Amber M. Johnson, Amadeo B. Biter, Ying Yuan, Lauren P. Cobb, David M. Gershenson, Amir A. Jazaeri, Karen H. Lu, Pamela T. Soliman, Shannon N. Westin, Elizabeth D. Euscher, Barrett C. Lawson, Richard K. Yang, Funda Meric-Bernstam, David S. Hong
Journal: Clinical Cancer Research (2024)

We aimed to describe RAS mutations in gynecologic cancers as they relate to clinicopathologic and genomic features, survival, and therapeutic implications.
Impact of Using Pre- and Post-Bronchodilator Spirometry Reference Values in a Chinese Population
Authors: Ke Huang, Xueyan Han, Zhaoyang Pan, Jianying Xu, Jianping Zhao, Xiangyan Zhang, Yuanlin Song, Jian Kang, Pixin Ran, Yumin Zhou, Huahao Shen, Fuqiang Wen, Kewu Huang, Yahong Chen, Yanfei Guo, Guangliang Shan, Sinan Wu, Tianjia Guan, Ting Yang, Chen Wang
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

Spirometry reference equations that are derived from a large, nationally representative general population are warranted in China, and the impact of using prebronchodilator (pre-BD) and post-BD spirometry reference values has yet to be assessed in Chinese populations.
Preventable Premature Deaths from the Five Leading Causes of Death in Nonmetropolitan and Metropolitan Counties, United States, 2010–2022
Authors: Macarena C. García, Lauren M. Rossen, Kevin Matthews, Gery Guy, Katrina F. Trivers, Cheryll C. Thomas, Linda Schieb, Michael F. Iademarco
Journal: MMWR Surveillance Summaries (2024)

A 2019 report quantified the higher percentage of potentially excess (preventable) deaths in U.S. nonmetropolitan areas compared with metropolitan areas during 2010-2017. In that report, CDC compared national, regional, and state estimates of preventable premature deaths from the five leading causes of death in nonmetropolitan and metropolitan counties during 2010-2017. This report provides estimates of preventable premature deaths for additional years (2010-2022).
Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505
Authors: Jordan M. Cloyd, Sarah Colby, Katherine A. Guthrie, Andy M. Lowy, E. Gabrielle Chiorean, Phillip Philip, Davendra Sohal, Syed Ahmad
Journal: Journal of the National Comprehensive Cancer Network (2024)

Background: Neoadjuvant therapy (NT) is increasingly used for patients with pancreatic ductal adenocarcinoma (PDAC), and yet reasons for not undergoing subsequent pancreatectomy are poorly understood. Given the importance of completing multimodality therapy, we investigated factors associated with failure to undergo surgical resection following NT for PDAC. Methods: SWOG S1505 was a multicenter phase II randomized trial of preoperative mFOLFIRINOX or gemcitabine/nab-paclitaxel prior to planned pancreatectomy for patients with potentially resectable PDAC. Associations between clinical, demographic, and hospital-level characteristics and receipt of surgical resection were estimated via multiple logistic regression. Differences in overall survival from 18 weeks postrandomization (scheduled time of surgery) according to resection status were assessed via Cox regression models. Results: Among 102 eligible patients, 73 (71.6%) underwent successful pancreatectomy, whereas 29 (28.4%) did not, primarily because of progression (n=11; 10.8%) or toxicity during NT (n=9; 8.8%). Weight loss during NT (odds ratio [OR], 0.34; 95% CI, 0.11–0.93) and the hospital’s city size (small: OR, 0.24 [95% CI, 0.07–0.80] and large: OR, 0.28 [95% CI, 0.10–0.79] compared with midsize) were significantly associated with a lower probability of surgical resection in adjusted models, whereas age, sex, race, body mass index, performance status, insurance type, geographic region, treatment arm, tumor location, chemotherapy delays/modifications, and hospital characteristics were not. Surgical resection following NT was associated with improved overall survival (median, 23.8 vs 10.8 months; P &lt;.01) even after adjusting for grade 3–5 adverse events during NT, performance status, and body mass index (hazard ratio, 0.55; 95% CI, 0.32–0.95). Conclusions: Failure to undergo resection following NT was relatively common among patients with potentially resectable PDAC and associated with worse survival. Although few predictive factors were identified in this secondary analysis of the SWOG S1505 randomized trial, further research must focus on risk factors for severe toxicities during NT that preclude surgical resection so that patient-centered interventions can be delivered or alternate treatment sequencing can be recommended.
Free TcO4 − in 99mTc-PSMA Scan
Authors: Pegah Sahafi, Kamran Aryana, Soroush Zarehparvar Moghadam, Kayvan Sadri, Emran Askari
Journal: Clinical Nuclear Medicine (2024)

Abstract In a recent 99m Tc-HYNIC-PSMA study conducted at our department, we examined 2 patients with prostate cancer referred for initial staging on the same day. The whole-body scans revealed radiotracer uptake in the gastric mucosa and thyroid glands, alluding to high levels of free TcO 4 − in the injected vial. The scans were repeated after confirming acceptable radiopharmaceutical purity of 97% (normal range, 95%–100%). Interestingly, 1 patient had liver metastases at presentation, which remained non–PSMA-avid after repeating the scan. We have reviewed this pitfall, which has been reported with many radiotracers, yet not reported with PSMA tracers.
High risk of progression for chronic major organ complications of sickle cell disease in adolescents and young adults: A long‐term neonatal cohort study
Authors: Marion Borgey, Isabelle Genty, Anoosha Habibi, Jean‐Benoit Arlet, Nathalie Dhedin, François Lionnet, Emmanuelle Bernit, Maryse Etienne Julan, Gylna Loko, Cécile Arnaud, Annie Kamdem, Serge Pissard, Eric Guémas, Clara Noizat, Corinne Pondarré
Journal: American Journal of Hematology (2024)
A Macrophage Membrane‐Functionalized, Reactive Oxygen Species‐Activatable Nanoprodrug to Alleviate Inflammation and Improve the Lipid Metabolism for Atherosclerosis Management
Authors: Kai Qu, Yuan Zhong, Li Zhu, Nianlian Mou, Yu Cao, Jie Liu, Shuai Wu, Meng Yan, Fei Yan, Jiawei Li, Cheng Zhang, Guicheng Wu, Kun Zhang, Xian Qin, Wei Wu
Journal: Advanced Healthcare Materials (2024)

Atherosclerosis (AS) management typically relies on therapeutic drug interventions, but these strategies typically have drawbacks, including poor site specificity, high systemic intake, and undesired side effects. The field of cell membrane camouflaged biomimetic nanomedicine offers the potential to address these challenges thanks to its ability to mimic the natural properties of cell membranes that enable enhanced biocompatibility, prolonged blood circulation, targeted drug delivery, and evasion of immune recognition, ultimately leading to improved therapeutic outcomes and reduced side effects. In this study, a novel biomimetic approach is developed to construct the M1 macrophage membrane-coated nanoprodrug (MM@CD-PBA-RVT) for AS management. The advanced MM@CD-PBA-RVT nanotherapeutics are proved to be effective in inhibiting macrophage phagocytosis and facilitating the cargo delivery to the activated endothelial cells of AS lesion both in vitro and in vivo. Over the 30-day period of nanotherapy, MM@CD-PBA-RVT is capable of significantly inhibiting the progression of AS, while also maintaining a favorable safety profile. In conclusion, the biomimetic MM@CD-PBA-RVT shows promise as feasible drug delivery systems for safe and effective anti-AS applications.
Long‐term effectiveness of eliglustat treatment: A real‐world analysis from the International Collaborative Gaucher Group Gaucher Registry
Authors: Pramod K. Mistry, Manisha Balwani, Joel Charrow, Jeremy Lorber, Claus Niederau, Jenny L. Carwile, Antonio Oliveira‐dos‐Santos, Maria Gabriela Perichon, Sefika Uslu Cil, Priya S. Kishnani
Journal: American Journal of Hematology (2024)

Abstract Gaucher disease type 1 (GD1) is known for phenotypic heterogeneity and varied natural history. Registrational clinical trials enrolled narrowly defined phenotypes, but greater diversity is encountered in clinical practice. We report real‐world outcomes with long‐term eliglustat treatment in adults with GD1 in the International Collaborative Gaucher Group Gaucher Registry. Among 5985 GD1 patients in the Registry as of January 6, 2023, 872 started eliglustat at ≥18 years old; of these, 469 met inclusion criteria. We compared clinical parameters at eliglustat initiation (i.e., baseline) and follow‐up in treatment‐naïve patients and used linear mixed models to estimate annual change from baseline in parameters among patients who switched to eliglustat after ≥1 year on enzyme replacement therapy. Over 4 years of follow‐up in non‐splenectomized treatment‐naïve patients, hemoglobin and platelet count increased, liver and spleen volume decreased, and total lumbar spine bone mineral density (BMD) Z‐score decreased slightly. Among non‐splenectomized switch patients, on average, hemoglobin decreased −0.030 (95% CI: −0.053, −0.008) g/dL ( N = 272) and platelet count increased 2.229 (95% CI: 0.751, 3.706) × 10 3 /mm 3 ( N = 262) annually up to 10 years; liver volume decreased (−0.009 [95% CI: −0.015, −0.003] MN) ( N = 102) and spleen volume remained stable (−0.070 [95% CI: −0.150, 0.010] MN) ( N = 106) annually up to 7 years; and total lumbar spine BMD Z ‐score increased 0.041 (95% CI: 0.015, 0.066) ( N = 183) annually up to 8 years. Among splenectomized switch patients, clinical parameters were stable over time. These long‐term, real‐world outcomes are consistent with the eliglustat clinical trials and emerging real‐world experience across the GD phenotypic spectrum.
Structural analysis of human IgE monoclonal antibody epitopes on dust mite allergen Der p 2
Authors: Alyssa Ball, Kriti Khatri, Jill Glesner, Lisa D. Vailes, Sabina Wünschmann, Scott A. Gabel, Geoffrey A. Mueller, Jian Zhang, R. Stokes Peebles, Martin D. Chapman, Scott A. Smith, Maksymilian Chruszcz, Anna Pomés
Journal: Journal of Allergy and Clinical Immunology (2024)
De Novo Metastatic Prostate Cancer Presenting With Atypical Lower-Limb Skeletal Metastases Detected on 68Ga-PSMA PET/CT
Authors: Alexander Yip, June Yap
Journal: Clinical Nuclear Medicine (2024)

Abstract Metastatic prostate cancer to the appendicular skeleton is rare. We present an 86-year-old man with undiagnosed prostate cancer presenting with unilateral foot pain. CT and MRI demonstrated a sclerotic midfoot suggestive of an infiltrative process. In view of an elevated PSA, metastatic disease was suspected, and bone scan confirmed osteoblastically active pelvic and lower-limb skeletal lesions. Subsequent prostate biopsy confirmed prostate adenocarcinoma. Staging 68 Ga-PSMA PET/CT demonstrated PSMA-avid intraprostatic malignancy with pelvic and right lower-limb skeletal metastases. This is an unusual case of de novo 68 Ga-PSMA–avid metastatic prostate cancer with atypical lower-limb skeletal metastases presenting with foot pain.
Cervicovaginal Metabolome and Tumor Characteristics for Endometrial Cancer Detection and Risk Stratification
Authors: Georgia M. Lorentzen, Paweł Łaniewski, Haiyan Cui, Nichole D. Mahnert, Jamal Mourad, Matthew P. Borst, Lyndsay Willmott, Dana M. Chase, Denise J. Roe, Melissa M. Herbst-Kralovetz
Journal: Clinical Cancer Research (2024)

Endometrial cancer is highly prevalent and lacking noninvasive diagnostic techniques. Diagnosis depends on histological investigation of biopsy samples. Serum biomarkers for endometrial cancer have lacked sensitivity and specificity. The objective of this study was to investigate the cervicovaginal environment to improve the understanding of metabolic reprogramming related to endometrial cancer and identify potential biomarker candidates for noninvasive diagnostic and prognostic tests.
Tracheoesophageal Fistula in a Tracheal Diverticulum Closed with Combined Esophagoscopy and Tracheoscopy: A Case Report
Authors: Run Tong, Jieru Lin, Ke Huang, Yingying Xu, Fang Liu, Mingming Deng, Jia Li, Guowu Zhou, Shiyu Du, Gang Hou
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

"Tracheoesophageal Fistula in a Tracheal Diverticulum Closed with Combined Esophagoscopy and Tracheoscopy: A Case Report." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma
Authors: Christie P.M. Verkleij, Chloe A. O'Neill, Marloes E.C. Broekmans, Kristine A. Frerichs, Wassilis S.C. Bruins, Carolien Duetz, Sandy Kruyswijk, Serena R. Baglio, Sheri Skerget, Rocio Montes de Oca, Sonja Zweegman, Raluca I. Verona, Tuna Mutis, Niels W.C.J. van de Donk
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Bispecific antibodies (BsAb) directed against B-cell maturation antigen (teclistamab) or the orphan G protein-coupled receptor GPRC5D (talquetamab) induce deep and durable responses in heavily pretreated patients with multiple myeloma. However, mechanisms underlying primary and acquired resistance remain poorly understood. Experimental Design: The anti–multiple myeloma activity of teclistamab and talquetamab was evaluated in bone marrow (BM) samples from patients with multiple myeloma. T-cell phenotype and function were assessed in BM/peripheral blood samples obtained from patients with multiple myeloma who were treated with these BsAb. Results: In ex vivo killing assays with 41 BM samples from BsAb-naive patients with multiple myeloma, teclistamab- and talquetamab-mediated multiple myeloma lysis was strongly correlated (r = 0.73, P &amp;lt; 0.0001). Both BsAb exhibited poor activity in samples with high regulatory T-cell (Treg) numbers and a low T-cell/multiple myeloma cell ratio. Furthermore, comprehensive phenotyping of BM samples derived from patients treated with teclistamab or talquetamab revealed that high frequencies of PD-1+ CD4+ T cells, CTLA4+ CD4+ T cells, and CD38+ CD4+ T cells were associated with primary resistance. Although this lack of response was linked to a modest increase in the expression of inhibitory receptors, increasing T-cell/multiple myeloma cell ratios by adding extra T cells enhanced sensitivity to BsAb. Further, treatment with BsAb resulted in an increased proportion of T cells expressing exhaustion markers (PD-1, TIGIT, and TIM-3), which was accompanied by reduced T-cell proliferative potential and cytokine secretion, as well as impaired antitumor efficacy in ex vivo experiments. Conclusions: Primary resistance is characterized by a low T-cell/multiple myeloma cell ratio and Treg-driven immunosuppression, whereas reduced T-cell fitness due to continuous BsAb-mediated T-cell activation may contribute to the development of acquired resistance.
Molecular and clinical presentation of <i>UBA1</i>-mutated myelodysplastic syndromes
Authors: Maria Sirenko, Elsa Bernard, Maria Creignou, Dylan Domenico, Andrea Farina, Juan E. Arango Ossa, Olivier Kosmider, Robert Hasserjian, Martin Jädersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Carmelo Gurnari, Matilde Yung Follo, Felicitas Thol, Lurdes Zamora, Ronald Feitosa Pinheiro, Andrea Pellagatti, Harold K. Elias, Detlef Haase, Birgitta Sander, Elisa Orna, Katharina Zoldan, Lea Naomi Eder, Wolfgang R. Sperr, Renate Thalhammer, Christina Ganster, Lionel Adès, Magnus Tobiasson, Laura Palomo, Matteo Giovanni Della Porta, Kety Huberman, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio P. S. Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Seishi Ogawa, Michaela Fontenay, Joop H. Jansen, Jose Cervera, Benjamin L. Ebert, Rafael Bejar, Peter L. Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, David B. Beck, Eva Hellström-Lindberg, Elli Papaemmanuil
Journal: Blood (2024)
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
Authors: João Carlos Locatelli, Juliene Gonçalves Costa, Andrew Haynes, Louise H. Naylor, P. Gerry Fegan, Bu B. Yeap, Daniel J. Green
Journal: Diabetes Care (2024)

This narrative review highlights the degree to which new antiobesity medications based on gut-derived nutrient-stimulated hormones (incretins) cause loss of lean mass, and the importance of resistance exercise to preserve muscle. Glucagon-like peptide 1 receptor agonists (GLP-1RA) induce substantial weight loss in randomized trials, effects that may be enhanced in combination with glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. Liraglutide and semaglutide (GLP-1RA), tirzepatide (GLP-1 and GIP receptor dual agonist), and retatrutide (GLP-1, GIP, and glucagon receptor triple agonist) are peptides with incretin agonist activity that induce ∼15-24% weight loss in adults with overweight and obesity, alongside beneficial impacts on blood pressure, cholesterol, blood glucose, and insulin. However, these agents also cause rapid and significant loss of lean mass (∼10% or ∼6 kg), comparable to a decade or more of aging. Maintaining muscle mass and function as humans age is crucial to avoiding sarcopenia and frailty, which are strongly linked to morbidity and mortality. Studies indicate that supervised resistance exercise training interventions with a duration >10 weeks can elicit large increases in lean mass (∼3 kg) and strength (∼25%) in men and women. After a low-calorie diet, combining aerobic exercise with liraglutide improved weight loss maintenance compared with either alone. Retaining lean mass during incretin therapy could blunt body weight (and fat) regain on cessation of weight loss pharmacotherapy. We propose that tailored resistance exercise training be recommended as an adjunct to incretin therapy to optimize changes in body composition by preserving lean mass while achieving fat loss.
Benchmarking clinical risk prediction algorithms with ensemble machine learning for the non-invasive diagnosis of liver fibrosis in NAFLD
Authors: Vivek Charu, Jane W. Liang, Ajitha Mannalithara, Allison Kwong, Lu Tian, W. Ray Kim
Journal: Hepatology (2024)

Ensemble machine-learning methods, like the superlearner, combine multiple models into a single one to enhance predictive accuracy. Here we explore the potential of the superlearner as a benchmarking tool for clinical risk prediction, illustrating the approach to identifying significant liver fibrosis among patients with NAFLD.
ASN Efforts to Address Challenges Highlighted in Recent Joint Global Consensus Statement Issued with ERA and ISN
Authors: Ryan Murray, Prabir Roy-Chaudhury, Samir Parikh
Journal: Journal of the American Society of Nephrology (2024)

1American Society of Nephrology, Washington, DC 2University of North Carolina Kidney Center, Chapel Hill, North Carolina and the WG (Bill) Hefner VA Medical Center, Salisbury, NC 3Department of Internal Medicine, Division of Nephrology, UT Southwestern, Dallas, Texas
Universal health coverage for children with cancer
Authors: None The Lancet Haematology
Journal: The Lancet Haematology (2024)

A huge global inequality related to cancer is the difference in overall survival of children with cancer in low-income and middle-income countries (LMICs; survival rates of <30%) versus those in high-income countries (HICs; survival rates of >80%). The 2018 WHO Global Initiative for Childhood Cancer has an overall goal to achieve at least 60% survival rates for all children with cancer by 2030, which will be achieved by implementing four pillars set out in the CureAll Framework: 1) centres of excellence and care networks to increase access to quality health services; 2) universal health coverage (UHC) and integration of childhood cancer; 3) regimens optimised for delivery of quality diagnostic and treatment services; and 4) evaluation and monitoring with information systems to improve outcomes.